High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment

Pediatric Research

Volumn 63, Issue 2, 2008, Pages 203-206

  D'Eufemia, Patrizia ^a   Finocchiaro, Roberto ^a   Celli, Mauro ^a   Zambrano, Anna ^a   Tetti, Martina ^a   Villani, Ciro ^a   Persiani, Pietro ^a   Mari, Emanuela ^a   Zicari, Alessandra ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; NERIDRONIC ACID; PROSTAGLANDIN E2;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; STRESS;

BONE AND BONES; CATALYSIS; CHILD; CHILD, PRESCHOOL; CYCLOOXYGENASE 2; DINOPROSTONE; DIPHOSPHONATES; FEMALE; HUMANS; INFANT; INFLAMMATION; MALE; MODELS, BIOLOGICAL; OSTEOGENESIS IMPERFECTA;

EID: 38349104019     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/PDR.0b013e31815efd63     Document Type: Article

References (20)

1. Heymann D, Rousselle AV 2000 Gp130 cytokine family and bone cells. Cytokine 12:1455-1468
2. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG 1995 The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res 313:36-46
3. 2 and epidermal growth factor. Coll Relat Res 2:185-195
4. 2 signaling system results in enhancement of osteoclastogenesis through effects on the osteoprotegerin\ receptor activator on nuclear factor-κB(RANK) ligand\RANK system. Endocrinology 146:1991-1998
5. Rauch F, Glorieux FH 2004 Osteogenesis imperfecta. Lancet 363:1377-1385
6. Sillence DO, Senn A, Danks DM 1979 Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116
7. Rauch F, Travers R, Parfitt AM, Glorieaux FH 2000 Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26:581-589
8. Glorieux FH 2007 Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics 119:S163-S165
9. Dehghani F, Conrad A, Kohl A, Korf HW, Hailer NP 2004 Clodronate inhibits the secretion of proinflammatory cytokines and NO by isolated microglial cells in excitotoxically injured organotypic hippocampal slice cultures. Exp Neurol 189:241-251
10. 2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187. Methods Find Exp Clin Pharmacol 28:361-367
11. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tatò L 2003 Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126-130
12. 2 receptors in the pathogenesis of arthritis. J Clin Invest 110:651-658
13. Buduneli E, Vardar S, Buduneli N, Berdeli AH, Turkoglu O, Baskesen A, Atilla G 2004 Effect of combined systemic administration of low-dose doxycycline and alendronate on endotoxin-induced periodontitis in rats. J Periodontol 75:1516-1523
14. 2 concentrations are associated with bone formation markers in ulcerative colitis patient. Prostaglandins Other Lipid Mediat 78:160-168
15. 2 production by cultured osteocytes. Am J Physiol 276:E171-E178
16. Burger EH, Klein-Nulend J 1999 Mechanotransduction in bone-role of the lacunocanalicular network. FASEB J 13:S101-S112
17. Zhao W, Byrne MH, Wang Y, Krane SM 2000 Osteocyte and osteoblast apoptosis and excessive bone deposition accompany failure of collagenase cleavage of collagen. J Clin Invest 106:941-949
18. Liu L, Hgarashi K, Haruyarma N, Sacki S, Shinoda H, Mitani H 2004 Effect of local administration of clodronate on orthodontic tooth movement and root resorption in rats. Eur J Orthod 26:469-473
19. 2 synthesis in the clonal osteoblast-like cell line MC3T3-E1. Prostaglandins Leukot Essent Fatty Acids 56:121-125
20. 2 production in compressed periodontal ligament cells. J Dent Res 85:757-760